Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL-2 in Ulcerative Colitis
NCT02200445Phase 1Completed
- Start
- Feb 2015
- Primary completion
- Oct 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aldesleukin in ulcerative colitis (UC). Primary endpoint: Number of Subjects With Serious and Non-serious Adverse Events at 8 weeks. Started Feb 2015; status: completed.
02
Drugs
aldesleukin
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02200445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200445.